Argen X SE ADR (ARGX)

Shares of Argen X SE ADR (ARGX) dropped by 25.12% from $452.58 to $338.91 in the trading on Wednesday, December 20, 2023. The reason why ARGX down today is due to the failure of Argenx's treatment, Vyvgart Hytrulo, in a Phase 3 study for pemphigus, an autoimmune skin-blistering disorder. The study showed that corticosteroids alone were effective in reducing the disease's autoantibodies in the placebo group. Argenx has decided to halt testing Vyvgart Hytrulo for pemphigus treatment and is delaying a decision on its potential use for bullous pemphigoid, marking the drug's second recent failure in autoimmune disease treatment.

Shares of Argen X SE ADR (ARGX) dropped by 10.17% from $495.77 to $445.34 in the trading on Tuesday, November 28, 2023. The reason why ARGX is down today is due to the announcement of disappointing results from the ADVANCE-SC study, which assessed VYVGART Hytrulo for treating primary immune thrombocytopenia (ITP). The study didn't meet its primary goal of sustaining platelet counts in chronic ITP patients.